Stockreport

Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma [Yahoo! Finance]

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF LBA-1 : Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) SAN DIEGO Dec. 10, 2024 /P [Read more]